Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures
Phase 2
Not yet recruiting
- Conditions
- Metastatic Cancer LungAdvanced Lung CancerCBNPC Cancer
- Interventions
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 115
- Registration Number
- NCT06713798
- Locations
- 🇫🇷
Centre Hospitalier Cote Basque, Bayonne, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Centre GF Leclerc, Dijon, France
Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for P53abn Endometrial Cancer
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 554
- Registration Number
- NCT06712472
- Locations
- 🇫🇷
Centre Hospitalier D'Albi, Albi, France
🇫🇷Institut Cancerologie de L'Ouest-Angers, Angers, France
🇫🇷Chu Besancon, Besancon, France
A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 50
- Registration Number
- NCT06508216
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
STEpwise Research Program to Promote INGeniouS ONline Supportive Solutions in the Relief of Cancer-related Fatigue
Not Applicable
Not yet recruiting
- Conditions
- Moderate or Severe Score of Cancer-related Fatigue (CRF)Cancer Diagnosis
- Interventions
- Device: Educational material plus self-management program - guided version with mental health professionalDevice: Educational material plus self-management program - self-administered versionDevice: Educational content
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 372
- Registration Number
- NCT06505590
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
PROACT is a Prospective Master Protocol for a Cohort Study Focused on Evaluating the Implementation of Integrated Proactive Supportive Care Pathways at Gustave Roussy
Recruiting
- Conditions
- Any Cancer
- Interventions
- Other: Supportive Care Pathway
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 210
- Registration Number
- NCT06479057
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer
Phase 1
Recruiting
- Conditions
- Oligometastatic DiseaseSolid Tumor, Adult
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 58
- Registration Number
- NCT06439888
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Gustave Roussy, Villejuif, France
Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal Adenocarcinoma
Phase 3
Recruiting
- Conditions
- Adult With Intermediate Low or Mid Rectal Adenocarcinoma
- Interventions
- Radiation: contact X-ray brachytherapy (CXB)
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 212
- Registration Number
- NCT06402864
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
CARE1 Pragmatic Clinical Trial
Phase 3
Recruiting
- Conditions
- Metastatic Kidney CancerMetastatic Kidney Carcinoma
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 1250
- Registration Number
- NCT06364631
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
🇨🇿Masarykův onkologický ústav, Masaryk Memorial Cancer Institute (MOU), Brno, Czechia
🇨🇿Fakultní nemocnice Hradec Králová, University Hospital Hradec Kralove (FNHK), Hradec Kralove, Czechia
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
Phase 3
Recruiting
- Conditions
- CancerColo-rectal CancerSoft Tissue SarcomaLung CancerPancreas Cancer
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 717
- Registration Number
- NCT06332274
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
Phase 1
Recruiting
- Conditions
- Breast Cancer MetastaticHER2 Low Breast CarcinomaHER2-positive Metastatic Breast CancerAdvanced Breast Cancer
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 152
- Registration Number
- NCT06298084
- Locations
- 🇫🇷
Gustave Roussy Institut, Villejuif, France